

## Tips for talking to your healthcare provider about the Prolaris® biopsy test

A good patient-clinician relationship should work like a partnership.  
Take an active role in finding out which prostate cancer treatment is right for you.

Prostate cancer is personal, your treatment should be too. The Prolaris test provides personalized information about the aggressiveness of your cancer, helping you to know if you are safe to forego treatment or if you should pursue treatment. Here are some tips to help you build a partnership with your doctor to get your genomic insights and start the conversation about why every newly diagnosed man needs Prolaris.



### Be prepared

Do your research on possible prostate cancer treatments, side-effects, and biomarker tests - like Prolaris. Come prepared to your cancer consultation with any information the doctor or staff may need to see. Make sure to bring along the *Prolaris Physician Quick Guide*.



### Be open and confident

First and foremost, remember that your doctor is on your side. You both want what's best for you, and helping you successfully manage your cancer is everyone's top priority. So just be open and honest about potential treatments or possible side-effects.



### Bring your support team

The support of family members or close friends can help facilitate the conversation with your doctor and help act as a co-advocate for your care at your next appointment.



### Discuss ordering the test

If you are ready for personalized genetic information to help you confidently make your treatment decision, ask your Urologist to order Prolaris today. Ordering is easy, your provider just needs to send the request form to Myriad and we take care of the rest.

Myriad, the Myriad logo, Prolaris, the Prolaris logo are either trademarks or registered trademarks of Myriad Genetics, Inc. in the United States and other jurisdictions.  
©2022 Myriad Genetics, Inc.

RCCPONEPGR/02-22

Use these tips to prepare for your upcoming appointment and share the accompanying materials with your doctor

# Healthcare professional quick guide to the Prolaris® biopsy test

Your patient has downloaded these materials to help facilitate a discussion with you about ordering the Prolaris test to help inform their prostate cancer treatment plan.

## What is Prolaris?

The Prolaris test from Myriad Genetics provides a personalized risk assessment of your patients' prostate cancer. Prolaris combines traditional clinical variables like PSA and Gleason with an independent molecular score to deliver the most prognostic information.<sup>1,7</sup>

## Prolaris advantage



Tumor biology improves initial treatment decisions for every man with prostate cancer



Reproducible studies provide confidence in receiving the most accurate results



2x more predictive than PSA and Gleason<sup>1</sup>



Only test repeatedly proven to work in untreated patients<sup>1,2,3,4</sup>

## How to order:

1. Fill out the Prolaris Biopsy test request form or download one here:
2. Email test request form to **Prolariscs@myriad.com** or fax to 801-883-3256
3. Test results sent directly to provider's office in around 2 weeks



## Learn more about our clinical utility and validity studies



## Insurance coverage and financial assistance



Medicare covers at 100%



>93% of patients pay \$0



Financial aid available

# The Prolaris biopsy test report

The Prolaris Biopsy result shows a patient's risk in relation to two validation thresholds. These thresholds identify candidates for active surveillance (AS) based on 10-year Disease-Specific Mortality (DSM) with conservative management and candidates for single- or multi-modal treatment based on 10-year metastasis (Mets) risk if treated.

## 1: Prolaris Molecular Score

Personalized tumor aggressiveness score

## 2: Risk Assessment

Clinical variables are combined with the Prolaris score to calculate your individualized cancer assessment

## 3: Prolaris recommendation for treatment path

## 4: Disease Specific Mortality (DSM)


10-year risk of prostate cancer specific death when choosing Active Surveillance


## 5: Metastatic Risk

10-year risk of cancer spreading when choosing a definitive treatment, like surgery or radiation

## 6: \*NEW\* Absolute Risk Reduction (ARR)

10-year risk of metastasis if adding hormone therapy to radiation therapy

  
MMM12361301



### Prolaris Biopsy Test Report

Summary

<b>ORDERING PHYSICIAN</b> Test HCP MD Test Medical Center 6609 BLANCO RD STE 200 SAN ANTONIO, TX 78216	<b>SPECIMEN ANALYZED</b> Tumor primary: Prostate Biopsy date: May 15, 2024 TRF received: Jun 4, 2024 Sample received: Jun 4, 2024 Report date: Jun 6, 2024	<b>PATIENT</b> Legal name: Pt Last Name Pt First Name Date of birth: Jan 2, 1962 Patient ID: Patient id Sex at birth: M Accession #: 07000015-BLD Requisition #: 07000015
--	---	--

Specimen(s) analyzed:

#### Prolaris molecular score and clinical variables

Personalized risks are calculated by a clinically validated, weighted algorithm that combines the Prolaris molecular score and clinical variables.

**1**  
**Prolaris molecular score**  
A measure of cell proliferation, independent of clinical variables.  

3.5

1.8Clinical range8.7

**2**  
**Clinical variables used for risk assessment & NCCN risk**  
Patient age at biopsy: 62  
Total PSA prior to this biopsy: 5.9  
Clinical T stage: T1c  
% Positive cores: < 34%  
Gleason score: 3+3=6 Group 1 (ISUP)<sup>1</sup>  
NCCN risk<sup>2</sup>: Very Low/Low

#### Test recommendation for possible treatment path

Based on the Prolaris molecular score and clinical variables, this patient may be a candidate for **active surveillance**.

Pt First Name Pt Last Name

**Active surveillance**  
Regular monitoring and testing per guideline recommendations.

**Single-modal treatment**  
Radiation therapy (RT) or surgery.

**Multi-modal treatment**  
Radiation therapy with androgen deprivation therapy (ADT) or surgery with intensified therapy per guideline recommendations.

#### Personalized risks results

**4**  
10-year risk of disease-specific mortality (DSM) with conservative management  
**1.8%**  
(95% CI:1.0-3.3%)

**5**  
10-year risk of prostate cancer metastasis with single-modal treatment  
**0.7%**  
(95% CI:0.3-1.9%)

**6**  
10-year risk of prostate cancer metastasis with RT plus ADT<sup>13</sup>  
**0.4%**  
(95% CI:0.1-1.5%)

**Prolaris®**  
Prostate Cancer Prognostic Test

Myriad Genetic Laboratories, Inc. 320 Wakara Way, Salt Lake City, Utah 84108 | 855.469.7765 | Fax 801.883.3256  
Myriad, the Myriad logo, Prolaris, and the Prolaris logo are either trademarks or registered trademarks of Myriad Genetics, Inc. in the United States and other jurisdictions. © 2024 PRD-0971 rev 16  
prolaris.com

CONFIDENTIAL

page 1 of 4

Have additional questions?

Prolaris customer service:  
855-469-7765

Email:  
ProlarisCSt@myriad.com

Visit our website:  
Prolaris.com

# Sources

<sup>1</sup>Cuzick J, et al. Prognostic value of a cell cycle progression signature for prostate cancer death in a conservatively managed needle biopsy cohort. BJC 2012;106(6):1095-1099

<sup>2</sup>Lin, D.W., et al. Identification of Men with Low-Risk Biopsy-Confirmed Prostate Cancer AS Candidates for Active Surveillance. Urologic Oncology: Seminars and Original Investigations. 2018; DOI:10.1016/J.UROLONC.2018.03.011

<sup>3</sup>Kaul S, et al. Clinical outcomes in men with prostate cancer who selected active surveillance using a clinical cell cycle risk score. Per Med. 2019;16(6):491-499. doi:10.2217/pme-2019-0084

<sup>4</sup>Cuzick J, et al. Validation of an RNA cell cycle progression score for predicting death from prostate cancer in a conservatively managed needle biopsy cohort. Br J Cancer 2015; 113:382–389

<sup>5</sup>Canter, C et al. Biopsy-delivered cell cycle progression score outperformed pathological upgrading or upstaging in predicting biochemical recurrence after surgery. Poster session presented at: Western AUA; 2018 October 28; Maui, HI

<sup>6</sup><https://prolaris.com/posters-and-medical-publications/#!#home>

<sup>7</sup>Tward JD, et al. The clinical cell-cycle risk (CCR) score is associated with metastasis after radiation therapy and provides guidance on when to forgo combined androgen deprivation therapy with dose-escalated radiation. International Journal of Radiation Oncology, Biology, Physics. 2021. DOI:<https://doi.org/10.1016/j.ijrobp.2021.09.03>



Myriad Genetics, Inc.  
320 Wakara Way  
Salt Lake City, UT  
84108

[Prolaris.com](https://prolaris.com)

Myriad, the Myriad logo, Prolaris, and the Prolaris logo are registered trademarks of Myriad Genetics, Inc. and its subsidiaries in the United States and other jurisdictions. ©2022 Myriad Genetic Laboratories, Inc.

RCCPONEPGR/07-24